<DOC>
	<DOC>NCT00417833</DOC>
	<brief_summary>Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG). Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.</brief_summary>
	<brief_title>Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment Completely studies Complications Tractional Detachment Endophthalmitis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>